Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis

Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indicati...

Full description

Saved in:
Bibliographic Details
Main Authors: A. O. Golovenko, I. L. Khalif, O. V. Golovenko, V. V. Veselov
Format: Article
Language:Russian
Published: Gastro LLC 2013-10-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/1233
Tags: Add Tag
No Tags, Be the first to tag this record!